Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Nov 25;5(1):vdad152. doi: 10.1093/noajnl/vdad152

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 6. — Changes in patient-derived glioblastoma (GBM) organoid (PGO) gene expression upon temozolomide (TMZ) treatment. (A) Volcano plot of differentially expressed genes (identified by RNAseq) between TMZ-treated and TMZ-untreated PGOs (N = 3). (B) Dose–response curves of TMZ and JNK inhibitor combination treatment in PGOs (N = 5). PGOs were treated with either 30 uM TMZ, 5 uM SP600125, or a combination. (C) Cell viability results of PGOs treated with different dosages of TMZ and JNK inhibitor. Data are shown for 3 PGOs combined. (D) Bliss scores showing the interaction between different concentrations of TMZ and JNK inhibitor for 3 PGOs combined. A Bliss score >10 confirms a synergistic reacting when both treatment options are combined.